Literature DB >> 8002883

Characterization of an avirulent mutant of a virulent avian Escherichia coli isolate.

L K Nolan1, R E Wooley, C W Giddings, J Brown.   

Abstract

A virulent, complement-resistant avian Escherichia coli isolate and its avirulent, complement-sensitive, transposon-insertion mutant were compared for the purpose of revealing structures associated with complement resistance. Both had a smooth lipopolysaccharide layer, contained traT, and lacked a capsule, but the mutant possessed a 16.2-kilodalton outer-membrane protein (OMP) not present in the wild-type. This protein may be the product of a coding region interrupted by transposon insertion. Such results suggest that an OMP greater than 16.2 kilodaltons in size may be responsible for the complement resistance and virulence of this wild-type E. coli.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8002883

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  4 in total

Review 1.  Resistance to serum complement, iss, and virulence of avian Escherichia coli.

Authors:  L K Nolan; S M Horne; C W Giddings; S L Foley; T J Johnson; A M Lynne; J Skyberg
Journal:  Vet Res Commun       Date:  2003-02       Impact factor: 2.459

2.  Characterization of Salmonella dublin and Salmonella typhimurium (Copenhagen) isolates from cattle.

Authors:  C A Brackelsberg; L K Nolan; J Brown
Journal:  Vet Res Commun       Date:  1997-08       Impact factor: 2.459

3.  Characterization of Escherichia coli isolates incriminated in colisepticaemia in mink.

Authors:  R J Tibbetts; D G White; N W Dyer; C W Giddings; L K Nolan
Journal:  Vet Res Commun       Date:  2003-07       Impact factor: 2.459

4.  Role of virulence factors in resistance of avian pathogenic Escherichia coli to serum and in pathogenicity.

Authors:  Melha Mellata; Maryvonne Dho-Moulin; Charles M Dozois; Roy Curtiss; Peter K Brown; Pascal Arné; Annie Brée; Clarisse Desautels; John M Fairbrother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.